The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Vascular‐targeting therapies for treatment of malignant disease
Open accessAbstract
BACKGROUND: Tumor endothelium represents a valuable target for cancer therapy. The vasculature plays a critical role in the survival and continued growth of solid tumor masses; in addition, the inherent differences between tumor blood vessels and blood vessels associated with normal tissue make the tumor vasculature a unique target on which to base the design of novel therapeutics, which may allow highly selective treatment of malignant disease. Therapeutic strategies that target and disrupt the already formed vessel networks of growing tumors are actively being pursued. The goal of these approaches is to induce a rapid and catastrophic shutdown of the vascular function of the tumor so that blood flow is arrested and tumor cell death due to the resulting oxygen and nutrient deprivation and buildup of waste products occurs. METHODS: Biologic approaches and small‐molecule drugs that can be used to damage tumor vasculature have been identified. Physiologic, histologic/morphologic, and immunohistochemical assessments have demonstrated that profound disruption of the tumor vessel network can be observed minutes to hours after treatment. The small‐molecule agents that have made the greatest advances in the clinical setting (5,6‐dimethylxanthenone‐4‐acetic acid [DMXAA], combretastatin A4 disodium phosphate [CA4DP], and ZD6126) are the focus of the current review. RESULTS: Loss of patent blood vessels, decreased tumor blood flow, extensive necrosis, and secondary ischemia‐induced tumor cell death have been well documented in a variety of preclinical tumor models treated with agents such as DMXAA, CA4DP, and ZD6126. The use of such agents in conjunction with irradiation and other chemotherapeutic agents has led to improved treatment outcomes. CONCLUSIONS: The targeting of tumors' supportive blood vessel networks could lead to improvements in cancer cure rates. It is likely that this approach will prove to be most efficacious when used in concert with conventional treatment strategies. Cancer 2004. © 2004 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1989) · PubMed · Cited by 3,343
Requirement of Vascular Integrin α v β 3 for Angiogenesis
Brooks, P. C., Clark, R. A. F., & Cheresh, D. A. (1994) · Science · doi:10.1126/science.7512751 · Cited by 3,020
Clinical Applications of Research on Angiogenesis
Folkman, J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512283332608 · Cited by 2,264
Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model
Arap, W., Pasqualini, R., & Ruoslahti, E. (1998) · Science · doi:10.1126/science.279.5349.377 · Cited by 2,054
Ausprunk, D. H., & Folkman, J. (1977) · Microvascular Research · doi:10.1016/0026-2862(77)90141-8 · Cited by 1,281
Eberhard, A., Kahlert, S., Goede, V., Hemmerlein, B., Plate, K. H., & Augustin, H. G. (2000) · PubMed · Cited by 873
Folkman, J. (1986) · PubMed · Cited by 863
Hahnfeldt, P., Panigrahy, D., Folkman, J., & Hlatky, L. (1999) · PubMed · Cited by 662
Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature.
Dark, G. G., Hill, S. A., Prise, V. E., Tozer, G. M., Pettit, G. R., & Chaplin, D. J. (1997) · PubMed · Cited by 622
Self-citationEndothelial proliferation in tumours and normal tissues: Continuous labelling studies
Hobson, B., & Denekamp, J. (1984) · British Journal of Cancer · doi:10.1038/bjc.1984.66 · Cited by 565
Prostate-specific membrane antigen is produced in tumor-associated neovasculature.
Chang, S. S., O’Keefe, D. S., Bacich, D. J., Reuter, V. E., Heston, W. D. W., & Gaudin, P. B. (1999) · PubMed · Cited by 471
Dowlati, A., Robertson, K., Cooney, M. M., Petros, W. P., Stratford, M. R. L., Jesberger, J. A., Rafie, N., Overmoyer, B. A., Makkar, V., Stambler, B. S., et al. (2002) · PubMed · Cited by 403
Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy
Denekamp, J. (1993) · The British Journal of Radiology · doi:10.1259/0007-1285-66-783-181 · Cited by 358
Burrows, F. J., Derbyshire, E. J., Tazzari, P. L., Amlot, P. L., Gazdar, A. F., King, S. W., Letarte, M., Vitetta, E. S., & Thorpe, P. E. (1995) · PubMed · Cited by 334
Tozer, G. M., Prise, V. E., Wilson, J., Locke, R. J., Vojnovic, B., Stratford, M. R. L., Dennis, M. F., & Chaplin, D. J. (1999) · PubMed · Cited by 323
Self-citationPhase I Clinical Trial of Weekly Combretastatin A4 Phosphate: Clinical and Pharmacokinetic Results
Rustin, G. J. S., Galbraith, S. M., Anderson, H., Stratford, M., Folkes, L. K., Sena, L., Gumbrell, L., & Price, P. M. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.185 · Cited by 307
Vascular attack as a therapeutic strategy for cancer
Denekamp, J. (1990) · CANCER AND METASTASIS REVIEW · doi:10.1007/bf00046365 · Cited by 264
Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate.
Chaplin, D. J., Pettit, G. R., & Hill, S. A. (1999) · PubMed · Cited by 252
Self-citationEndothelial cell proliferation as a novel approach to targeting tumour therapy
Denekamp, J. (1982) · British Journal of Cancer · doi:10.1038/bjc.1982.16 · Cited by 249
Nauts, H. C., FOWLER, G. A., & Fh, B. (1953) · PubMed · Cited by 247
Nilsson, F., Kosmehl, H., Zardi, L., & Neri, D. (2001) · PubMed · Cited by 235
Assessment of Pharmacodynamic Vascular Response in a Phase I Trial of Combretastatin A4 Phosphate
Anderson, H. L., Yap, J. T., Miller, M. P., Robbins, A., Jones, T., & Price, P. M. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.186 · Cited by 217
In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug
Grosios, K., Holwell, S. E., McGown, A. T., Pettit, G. R., & Bibby, M. C. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6692174 · Cited by 213
Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models.
Blakey, D. C., Westwood, F. R., Walker, M., et al. (2002) · PubMed · Cited by 176
Baguley, B. C., Holdaway, K. M., Thomsen, L. L., Zhuang, L., & Jonathan Zwi, L. (1991) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(91)90391-p · Cited by 172
Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy
Siemann, D. W., Mercer, E., Lepler, S., & Rojiani, A. M. (2002) · International Journal of Cancer · doi:10.1002/ijc.10316 · Cited by 166
Self-citationGalbraith, S. M., Chaplin, D. J., Lee, F., Stratford, M. R. L., Locke, R. J., Vojnovic, B., & Tozer, G. M. (2001) · PubMed · Cited by 165
Self-citationGalbraith, S. M., Rustin, G. J. S., Lodge, M. A., Taylor, N. J., Stirling, J., Jameson, M. B., Thompson, P. I., Hough, D., Gumbrell, L. A., & Padhani, A. R. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.144 · Cited by 144
Veenendaal, L. M., Jin, H., Ran, S., Cheung, L. H., Navone, N. M., Marks, J. W., Waltenberger, J. L., Thorpe, P. E., & Rosenblum, M. G. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122157899 · Cited by 142
Vascular occlusion and tumour cell death
Denekamp, J., Hill, S. A., & Hobson, B. (1983) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(83)90426-1 · Cited by 140
Jameson, M. B., Thompson, P. I., Baguley, B. C., Evans, B. D., Harvey, V. J., Porter, D. J. T., McCrystal, M. R., Small, M., Bellenger, K., Gumbrell, L. A., et al. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600992 · Cited by 136
Li, L., Rojiani, A. M., & Siemann, D. W. (1998) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(98)00320-4 · Cited by 130
Self-citationHorsman, M. R., Christensen, K. L., & Overgaard, A. J. (1989) · International Journal of Hyperthermia · doi:10.3109/02656738909140442 · Cited by 116
Self-citationTumour vasculature as a target for cancer therapy.
Chaplin, D. J., & Dougherty, G. J. (1999) · PubMed · Cited by 116
Self-citationRole of tumor necrosis factor in flavone acetic acid-induced tumor vasculature shutdown.
Mahadevan, V., Malik, S., Meager, A., Fiers, W., Lewis, G. P., & Hart, I. R. (1990) · PubMed · Cited by 111
Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors
Murata, R., Siemann, D. W., Overgaard, J., & Horsman, M. R. (2001) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(01)00384-x · Cited by 109
Self-citationPhilpott, M., Baguley, B. C., & Ching, L. (1995) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00689199 · Cited by 108
Pedley, R. B., Hill, S. A., Boxer, G., Flynn, A. A., Boden, R. W., Watson, R., Dearling, J. L. J., Chaplin, D. J., & Beǵent, R. H. J. (2001) · PubMed · Cited by 108
Self-citationRustin, G. J. S., Bradley, C., Galbraith, S. M., Stratford, M. R. L., Loadman, P. M., Waller, S., Bellenger, K., Gumbrell, L. A., Folkes, L. K., & Halbert, G. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600885 · Cited by 105
Lash, C., Li, A. E., Rutland, M. D., Baguley, B., Zwi, L. J., & Wilson, W. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.512 · Cited by 99
Wilson, W. R., Li, A., Cowan, D. M., & Siim, B. G. (1998) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(98)00358-7 · Cited by 97
Grosios, K., Loadman, P. M., Swaine, D. J., et al. (2000) · PubMed · Cited by 81
Murata, R., Siemann, D. W., Overgaard, J., & Horsman, M. R. (2001) · Radiation Research · doi:10.1667/0033-7587(2001)156[0503:itrbcr]2.0.co;2 · Cited by 80
Self-citationPruijn, F. B., van Daalen, M., Holford, N. H. G., & Wilson, W. R. (1997) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050611 · Cited by 78
Vascular endothelial growth factor and vascular targeting of solid tumors.
Brekken, R. A., & Thorpe, P. E. (2001) · PubMed · Cited by 73
Proliferation kinetics of endothelial and tumour cells in three mouse mammary carcinomas
Hirst, D. G., Denekamp, J., & Hobson, B. (1982) · Cell Proliferation · doi:10.1111/j.1365-2184.1982.tb01044.x · Cited by 73
Siemann, D. W., & Rojiani, A. M. (2002) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(02)03919-6 · Cited by 65
Self-citationR. Murata, J. O. (2001) · International Journal of Radiation Biology · doi:10.1080/09553000010007695 · Cited by 65
DMXAA: An antivascular agent with multiple host responses
Baguley, B. C., & Ching, L. (2002) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(02)03920-2 · Cited by 64
Targeting tumor blood vessels: an adjuvant strategy for radiation therapy
Siemann, D. W., Warrington, K. H., & Horsman, M. R. (2000) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(00)00243-7 · Cited by 62
Self-citationUse of Arsenic Trioxide as an Antivascular and Thermosensitizing Agent in Solid Tumors
Griffin, R. J., Lee, S. H., Rood, K. L., Stewart, M. J., Lyons, J. C., Lew, Y. S., Park, H. J., & Song, C. W. (2000) · Neoplasia · doi:10.1038/sj.neo.7900123 · Cited by 60
Cliffe, S., Taylor, M. L., Rutland, M. D., et al. (1994) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(94)90292-5 · Cited by 60
Horsman, M. R., & Murata, R. (2003) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(03)00769-7 · Cited by 57
Self-citationBasic clinical radiobiology for radiation oncologists
Steel, G. G. (1993) · Edward Arnold eBooks · Cited by 55
Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid
Laws, A. L., Matthew, A., Double, J. A., & Bibby, M. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.234 · Cited by 50
Targeting the tumor blood vessel network to enhance the efficacy of radiation therapy
Siemann, D. W., & Shi, W. (2003) · Seminars in Radiation Oncology · doi:10.1053/srao.2003.50005 · Cited by 44
Self-citationLi, L., Rojiani, A. M., & Siemann, D. W. (2002) · Acta Oncologica · doi:10.1080/028418602317314127 · Cited by 43
Self-citationCombretastatin A-4 and hyperthermia;a potent combination for the treatment of solid tumors
Eikesdal, H. P., Bjerkvig, R., Mella, O., & Dahl, O. (2001) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(00)00318-2 · Cited by 38
Cited by
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Angiogenesis as a therapeutic target
Ferrara, N., & Kerbel, R. S. (2005) · Nature · doi:10.1038/nature04483 · Cited by 2,653
Kerbel, R. S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0706596 · Cited by 1,948
Siemann, D. W. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.05.001 · Cited by 611
Self-citationTherapy-Induced Acute Recruitment of Circulating Endothelial Progenitor Cells to Tumors
Shaked, Y., Ciarrocchi, A., Franco, M., Lee, C. R., Man, S., Cheung, A. M., Hicklin, D. J., Chaplin, D., Foster, F. S., Benezra, R., et al. (2006) · Science · doi:10.1126/science.1127592 · Cited by 570
Self-citation
Metadata
- Authors
- Siemann, D. W., Chaplin, D. J., & Horsman, M. R.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2004-06-02
- Volume
- 100
- Issue
- 12
- Pages
- 2491-2499
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2000970414
- Cited by
- 310
- References
- 58
- FWCI
- 9.73
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.